Edit
4D Molecular Therapeutics
https://www.4dmoleculartherapeutics.com/Last activity: 09.02.2022
Active
We are 4DMT! Our mission is to boldly innovate to unlock the full potential of gene therapy for countless patients. 4DMT is a leader in next-generation AAV gene therapy discovery through its proprietary therapeutic vector evolution platform that empowers us to invent optimized and proprietary AAV vectors, each specifically tailored for the treatment of a rare disease with a high unmet medical need. We strive to become the most impactful company in the gene therapy industry.
We are pioneering the development of precision gene therapies based on our proprietary AAV vectors. Our transformative discovery platform, Therapeutic Vector Evolution, enables our “disease first” approach to product discovery, design and development. We use our platform to discover custom and proprietary AAVs designed for specific tissues and diseases, which we believe will allow us to overcome known limitations of conventional AAV vectors and potentially address a broad range of both rare and large market diseases. Based on our Target Vector Profile for a disease, we select customized capsids in non-human primates from an estimated over one billion vector capsid sequences in our 37 proprietary and diverse AAV vector libraries as of August 1, 2019. We are developing a diverse pipeline in a broad range of therapeutic areas of wholly owned and partnered programs.
We seek the best in the industry who identify with our mission and innovative results-driven approach. Our 4 Guiding Principles drive our actions, and they are: Dare to Cure (create big dreams for patients, innovate and take calculated risks to achieve them); Break Boundaries (questioning and moving beyond the status quo); Beyond Yourself (we are patient and team focused); and Prepare & Executive Relentlessly (be proactive and start with the end in mind).
We are pioneering the development of precision gene therapies based on our proprietary AAV vectors. Our transformative discovery platform, Therapeutic Vector Evolution, enables our “disease first” approach to product discovery, design and development. We use our platform to discover custom and proprietary AAVs designed for specific tissues and diseases, which we believe will allow us to overcome known limitations of conventional AAV vectors and potentially address a broad range of both rare and large market diseases. Based on our Target Vector Profile for a disease, we select customized capsids in non-human primates from an estimated over one billion vector capsid sequences in our 37 proprietary and diverse AAV vector libraries as of August 1, 2019. We are developing a diverse pipeline in a broad range of therapeutic areas of wholly owned and partnered programs.
We seek the best in the industry who identify with our mission and innovative results-driven approach. Our 4 Guiding Principles drive our actions, and they are: Dare to Cure (create big dreams for patients, innovate and take calculated risks to achieve them); Break Boundaries (questioning and moving beyond the status quo); Beyond Yourself (we are patient and team focused); and Prepare & Executive Relentlessly (be proactive and start with the end in mind).
Location: United States, California, Emeryville
Employees: 51-200
Total raised: $165M
Founded date: 2013
Investors 8
Funding Rounds 2
Date | Series | Amount | Investors |
16.06.2020 | Series C | $75M | - |
06.09.2018 | Series B | $90M | - |
Mentions in press and media 10
Date | Title | Description |
09.02.2022 | 4D Molecular Therapeutics Announces Updated Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease at the 18th Annual WORLDSymposium | Following discontinuation of ERT, AGA activity was stable at 14-fold mean normal level through week 37 (Patient 1) and stable at 10-fold mean normal levels through week 20 (Patient 3) Preliminary clinical data suggest encouraging improvemen... |
06.10.2021 | Aetion to collaborate with UK's NICE on RWE; 4D's cystic fibrosis gene therapy cleared for clinical trials | New York-based real world evidence, or RWE, firm Aetion is teaming up with the National Institute for Health and Care Excellence in the United Kingdom to analyze data such as hospital records, prescription records and mo... |
18.11.2020 | 4DMT shoots for a $75M IPO, its second attempt to go public with its gene therapy vector programs | Just a few months after withdrawing its IPO filing, 4D Molecular Therapeutics is seeking to go public once again. The Emeryville, CA-based company submitted a new S-1 on Tuesday, detailing plans for a $75 million raise ... |
16.06.2020 | 4D Molecular Therapeutics Raises $75 Million in Series C Financing | EMERYVILLE, Calif.--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced the closing of its $75 million Series C financin... |
07.09.2018 | Term Sheet — Friday, September 7 | THREE THINGS Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop THE LATEST IN ELON MUSK: Well, um, how do I put this? In a spectacularly bold move after everything that’s happened, Tesla CEO... |
06.09.2018 | 4D Molecular Therapeutics Raises $90M in Series B Financing | 4D Molecular Therapeutics, an Emeryville, Calif.-based gene therapy company, closed a $90m Series B financing. The round was led by Viking Global Investors, with participation from ArrowMark Partners, Janus Henderson Investors, The Biotechn... |
06.09.2018 | 4D Molecular Therapeutics Lands $90M | EMERYVILLE, CA, 4D Molecular Therapeutics announced the closing of its $90 million Series B Financing. >> Click here for more funding data on 4D Molecular Therapeutics >> To export 4D Molecular Therapeutics funding data to P... |
05.09.2018 | 4D raises $90M to move gene therapies into clinical testing with AstraZeneca and Roche | Gene therapy company 4D Molecular Therapeutics has raised $90 million in venture capital funds, with plans to advance its vector platform and pipeline of treatments that use adeno-associated viruses to insert genes into cells. Its lead prog... |
05.09.2018 | 4D raises $90M to move gene therapies into clinical testing with AstraZeneca and Roche W h i t e p a p e r Weighing the Costs: | Gene therapy company 4D Molecular Therapeutics has raised $90 million in venture capital funds, with plans to advance its vector platform and pipeline of treatments that use adeno-associated viruses to insert genes into cells. Sponsored by ... |
27.07.2015 | Horizon to invest up to £10m leveraged funding in molecular cancer therapeutics | Horizon to invest up to £10m leveraged funding in molecular cancer therapeutics 27-07-2015 Horizon Discovery Group plc, the international life science company supplying research tools and services that power genomics research and the develo... |